Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The shares were purchased at an average cost of $32.85 per share, with a total value of $1,642,500.00. Following the completion of the purchase, the insider now owns 5,548,799 shares of the company’s stock, valued at approximately $182,278,047.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Radius Health, Inc. (RDUS) traded down $0.30 during mid-day trading on Friday, hitting $28.10. The company had a trading volume of 1,288,900 shares, compared to its average volume of 961,724. Radius Health, Inc. has a 52-week low of $27.16 and a 52-week high of $55.97. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.
Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter last year, the business posted ($1.07) EPS. research analysts expect that Radius Health, Inc. will post -5.4 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Radius Health, Inc. (RDUS) Major Shareholder Acquires $1,642,500.00 in Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/11/radius-health-inc-rdus-major-shareholder-growth-n-v-biotech-purchases-50000-shares.html.
Several institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new stake in Radius Health during the 1st quarter worth approximately $105,000. Sei Investments Co. grew its position in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Advisor Group Inc. grew its position in shares of Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 46 shares in the last quarter. Finally, Blair William & Co. IL acquired a new position in Radius Health in the second quarter valued at approximately $205,000.
A number of equities analysts recently commented on RDUS shares. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Maxim Group reissued a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a research note on Monday, July 31st. Finally, Cantor Fitzgerald set a $65.00 price target on Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $51.00.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.